Where an aging population desires to look young and beautiful, Cramer sees a potential in Allergan , a specialty pharmaceutical company that is known for a range of popular products: Botox, breast implants, gastric bands to fight obesity. The company also produces juvederm, which is a dermal filler to reduce wrinkles, aczone to fight acne and Latisse for fuller eyelashes. It also has a non-aesthetic, medical eye-care business. If the company's second-quarter earnings results are any indication, Allergan's product line is doing well.
On Monday, the Irvine, Calif.-based company reported a better-than-expected quarter, which delivered earnings of 85 cents a share. It beat the Street's expectations by 4 cents on stronger than expected revenues that are up 10% and Cramer noted it improved margins, too. Some investors didn't like the guidance, but the Mad Money host said the stock has continued to rise thanks to a host of trends.
"People spending more to look good as the economy recovers, people aging with eye problems, the woes of obesity," Cramer said. "All of these trends coalesced to give the stock a real pop when it reported."
To learn more about what's ahead for the pharma name, Cramer invited Allergan CEO David Pyott onto Wednesday's Mad Money. Watch the video to hear the full conversation.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org